Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.
RemeGen Co., Ltd. has scheduled a board meeting for March 27, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The board will also consider whether to recommend a dividend, a decision that could affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also reconfirms the current composition of RemeGen’s board, listing its executive, non-executive and independent non-executive directors. This underscores the company’s adherence to Hong Kong corporate governance requirements as it approaches a key financial reporting and capital allocation decision for investors.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$82.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 9995. The company operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a standard listed-company governance structure focused on drug development and commercialization in healthcare markets.
Average Trading Volume: 3,824,481
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$63.7B
See more data about 9995 stock on TipRanks’ Stock Analysis page.